Natera Inc.
Natera, Inc. Stockholders Approve Equity Incentive Plan Amendment
Summary
On June 12, 2025, Natera, Inc. held its Annual Meeting of Stockholders, where the Company's stockholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan, increasing the shares reserved for issuance under the Plan by 3.6 million shares of the Company's common stock. The meeting also included votes on the election of directors, ratification of Ernst & Young LLP as the Company's independent registered public accounting firm, an advisory vote on the compensation of the Company's named executive officers, and the approval of the aforementioned equity incentive plan amendment. Detailed results of the votes are provided in the filing.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement